MedTrace Logo

Study on Performance and Safety of Sentinox in the Prevention of Acute Respiratory Infections (ARI)

NCT05499780 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 144

Last updated 2023-11-24

No results posted yet for this study

Summary

This is a post market, single-center, randomized, controlled, clinical study to assessTo evaluate the performance of self-administered Sentinox intranasal spray in preventing ARI caused by at least one respiratory virus

Conditions

  • Healthy Volunteers

Interventions

DEVICE

Sentinox

The treatment will be administered in a dose of 0.5 ml into each nostril (5 sprays) per 3 times/day (8 am, 2 pm and 8 pm), for 21 days from Visit 1.

Sponsors & Collaborators

  • APR Applied Pharma Research s.a.

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
63 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-11-07
Primary Completion
2023-02-27
Completion
2023-09-13

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05499780 on ClinicalTrials.gov